https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Comparison of capecitabine concentrations determined by microsampling versus plasma concentrations for therapeutic drug monitoring: a pilot study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54339 Wed 28 Feb 2024 15:10:12 AEDT ]]> Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33907 Wed 23 Jan 2019 10:40:24 AEDT ]]> Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome Some of the Challenges of Developing Medicinal Cannabis from Botanical Origins https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48609 Wed 22 Mar 2023 09:00:58 AEDT ]]> Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54540 Tue 27 Feb 2024 20:42:11 AEDT ]]> A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49592 Tue 23 May 2023 11:55:57 AEST ]]> An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43175 Tue 13 Sep 2022 16:10:37 AEST ]]> Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44058 Thu 06 Oct 2022 09:55:23 AEDT ]]> Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29616 1000). Conclusion: Although data from randomised clinical trials on the clinical impact of sunitinib TDM are lacking, our findings support implementation of sunitinib TDM in clinical practice. For rare cancers with well-defined exposure–response relationships, modelling and simulation might allow the optimisation of dosing strategies when clinical trials cannot be performed due to low number of patients.]]> Thu 03 Feb 2022 12:18:41 AEDT ]]> Clinical consequences of a miscalibrated digoxin immunoassay https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25158 Sat 24 Mar 2018 07:14:29 AEDT ]]> Implementation of a centralised aminoglycoside monitoring service https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23087 Sat 24 Mar 2018 07:12:34 AEDT ]]> Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47896 Mon 06 Feb 2023 13:46:00 AEDT ]]> Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49507 Fri 19 May 2023 16:35:01 AEST ]]> Dried Blood Spot Sampling in the Monitoring of Anticancer Therapy for Solid Tumors: A Systematic Review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53882 0.872; correlation coefficient, r = 0.87, P < 0.0001). Conclusions: DBS provides an alternative sampling strategy for the TDM of many anticancer drugs. Further research is required to establish a standardized approach for sampling and processing DBS samples to allow future implementation.]]> Fri 19 Jan 2024 14:22:43 AEDT ]]>